The acquisition significantly increases Amneal's leverage and share count while adding a biosimilars pipeline. Monitor upcoming quarterly reports for revenue contribution from Kashiv's partnered products (omalizumab, lanreotide) and progress on regulatory milestones that trigger contingent payments. The going concern qualification in Kashiv's pre-acquisition filings highlights execution risk.
Price Chart
Executive Summary
Amneal Pharmaceuticals filed an 8-K/A providing unaudited pro forma financial statements for its acquisition of Kashiv BioSciences, which closed on August 10, 2026. The total consideration was approximately $1.31 billion, consisting of $266 million in cash, 28.9 million Amneal shares valued at $492 million, and contingent milestone/royalty payments valued at $389 million. The acquisition was financed through $350 million in incremental term loan borrowings and $180 million from the revolving credit facility, adding significant leverage.
Key Facts
- Amneal completed the acquisition of Kashiv BioSciences on August 10, 2026 for total consideration of approximately $1.31 billion.
- Consideration included $266 million in cash, 28.9 million shares of Class A common stock valued at $492 million, and contingent consideration of $389 million.
- The acquisition was funded by $350 million in incremental term loan borrowings and $180 million from the revolving credit facility.
- Pro forma combined net revenue for the six months ended June 30, 2026 was $1.524 billion, with net income attributable to Amneal of $17.2 million.
- Pro forma combined net loss attributable to Amneal for the year ended December 31, 2025 was $78.2 million.
- Kashiv had a going concern qualification in its audited financial statements as of December 31, 2025, with $106.3 million cash used in operations that year.
- Amneal recorded $1.004 billion in identifiable intangible assets from the acquisition, primarily in-process R&D ($963 million).
- Goodwill of $170 million was recorded as the residual of the purchase price allocation.
- The pro forma combined company had total assets of $5.25 billion and total liabilities of $4.66 billion as of June 30, 2026.
- Pro forma basic EPS for the six months ended June 30, 2026 was $0.05, down from Amneal's standalone $0.38.
Financial Impact
Total consideration of $1.31 billion; $350 million in new term loan debt and $180 million in revolver borrowings added; $1.004 billion in intangible assets recorded; pro forma net income of $17.2 million for H1 2026 vs. standalone $119.9 million.
Risk Factors
- Integration risk and execution risk on Kashiv's pipeline of biosimilars and complex generics.
- Significant increase in leverage: $350 million incremental term loan and $180 million revolver draw.
- Dilution from 28.9 million new shares (approximately 9% increase in basic share count).
- Contingent consideration of up to $350 million in milestones and 12-year royalty obligations could pressure future cash flows.
- Kashiv had a going concern qualification and negative operating cash flow of $106 million in 2025.
- Preliminary purchase price allocation subject to change, which could affect future amortization and impairment charges.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K/A Filing (Primary) | 0001140361-26-040656 |
| Document: ef20082879_ex99-1.htm | 0001140361-26-040656 |
| Document: ef20082879_ex99-2.htm | 0001140361-26-040656 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K/A | $20.38 | awaiting T+60 | — | $21.02 (+3.14%) |
Sep 18, 2026 5w ago | Press Release | $20.16 | awaiting T+60 | — | $21.02 (+4.27%) |
Aug 16, 2026 10w ago | Institutional Cluster | $18.42 | awaiting T+60 | — | $21.02 (+14.12%) |
Aug 14, 2026 10w ago | Insider Cluster | $18.42 | awaiting T+60 | — | $21.02 (+14.12%) |
Aug 13, 2026 10w ago | Insider Cluster | $18.15 | awaiting T+60 | — | $21.02 (−15.81%) |
Aug 10, 2026 11w ago | 8-K | $17.10 | awaiting T+60 | — | $21.02 (+22.92%) |
Jul 30, 2026 12w ago | DEFA14A | $18.50 $20.38 | ▲ +10.16% | ▲ +7.70% | $21.02 (+13.62%) |
Jul 17, 2026 14w ago | Press Release | $17.85 $20.03 | ▲ +12.21% | ▲ +7.53% | $21.02 (+17.76%) |
Jun 29, 2026 17w ago | DEFM14A | $17.29 $19.50 | ▲ +12.78% | ▲ +8.40% | $21.02 (+21.57%) |
Jun 29, 2026 17w ago | Press Release | $17.29 $19.50 | ▲ +12.78% | ▲ +8.40% | $21.02 (+21.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers